aAVCs are loaded with exogenous glycolipid ligands, such as agalactosylceramide (a‐GalCer), presented on CD1d moleculeActivate iNKT to allow iNKT and NK cells to kill aAVCs, releasing the tumour‐associated antigenDrive generation of antigen‐specific T cells via cross‐presentation by DCsEpigenetic‐targeting drugs could represent another promising option for combination with aAVC therapy. Here, CD1D is linked to neoplasm.